Cara Therapeutics Inc T.CARA

Primary Symbol: CARA

Healthcare Cannabis

Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

NDAQ:CARA - Post by User

Cara Therapeutics Inc > Like this too but don't understand share structure ...

<< Previous

Bullboard Posts

Next >>

Comment by Froyalmac09on Mar 31, 2016 3:35pm

187 Views

Post# 24716734

RE:Like this too but don't understand share structure ...

Went back and read again. I think there are just different forms of sub shares those that vote and those that don't ( those traded ) . Press release indicates offering will be between $26 to $30 with Fairfax backing the $26 at least price. Probably see something soon.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?